Keyphrases
Crohn's Disease
100%
Ulcerative Colitis
94%
Inflammatory Bowel Disease
59%
Japan
52%
Japanese Patients
27%
Adalimumab
19%
Confidence Interval
18%
Small Bowel Injury
17%
Double-balloon Enteroscopy
16%
Clinical Remission
16%
Mucosal Healing
15%
Small Intestine
15%
Capsule Endoscopy
14%
Remission
14%
Colonoscopy
13%
Induction Therapy
13%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
13%
Active Ulcerative Colitis
13%
Risk Factors
13%
Ulcerative Colitis Patient
12%
Odds Ratio
12%
Infliximab
12%
Stricture
12%
Surveillance Colonoscopy
11%
Vedolizumab
11%
Ulcer
11%
Adverse Events
10%
Gastroesophageal Reflux Disease
10%
Thiopurines
10%
Mucosa
10%
Apheresis
10%
Endoscopic Findings
9%
Immunomodulator
9%
Endoscopic Diagnosis
9%
Patency Capsule
9%
Colon
9%
Maintenance Therapy
9%
Proton Pump Inhibitors
9%
Randomized Controlled Trial
8%
Placebo
8%
Granulocytes
8%
Monocytes
8%
Tumor
8%
Irritable Bowel Syndrome
8%
Loss of Response
8%
Clinical Features
8%
Anti-tumor Necrosis Factor (anti-TNF)
8%
Tumor Necrosis Factor-α
7%
Endoscopy
7%
Registry Study
7%
Medicine and Dentistry
Ulcerative Colitis
62%
Crohn's Disease
53%
Patient with Ulcerative Colitis
46%
Patient with Crohn's Disease
38%
Inflammatory Bowel Disease
35%
Colonoscopy
25%
Patient with Inflammatory Bowel Disease
21%
Disease
21%
Capsule Endoscopy
19%
Double-Balloon Enteroscopy
16%
Stricture
16%
Ulcer
15%
Neoplasm
14%
Endoscopy
13%
Biopsy Technique
12%
Gastrointestinal Bleeding
12%
Placebo
12%
Vedolizumab
11%
Adverse Event
10%
Colon
10%
Mucosa
9%
Stenosis
9%
Randomized Controlled Trial
9%
Odds Ratio
8%
Venous Ulcer
8%
Enteropathy
8%
Intestine Injury
8%
Infliximab
8%
Apheresis
8%
Malignant Neoplasm
8%
Nonsteroid Antiinflammatory Agent
7%
Surgery
7%
Prevalence
7%
Clinical Feature
7%
Narrow Band Imaging
7%
Tumor Necrosis Factor
7%
Rectal Bleeding
7%
Colitis
7%
Granulocyte
6%
Balloon Dilatation
6%
Disease Management
6%
Proton-Pump Inhibitor
6%
Endoscopic Submucosal Dissection
6%
Colon Carcinoma
5%
Stomach Ulcer
5%
Clinical Trial
5%
Immunomodulating Agent
5%
Budesonide
5%
Vermiform Appendix
5%
Interim Analysis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
65%
Ulcerative Colitis
60%
Inflammatory Bowel Disease
33%
Remission
31%
Disease
18%
Ulcer
16%
Adalimumab
15%
Tumor Necrosis Factor
14%
Adverse Event
14%
Placebo
14%
Neoplasm
13%
Intestine Injury
12%
Non-Steroidal Anti-Inflammatory Drug
11%
Mercaptopurine
10%
Infliximab
10%
Disease Activity
9%
Injury
9%
Prospective Study
8%
Prevalence
8%
Pharmacokinetics
8%
Gastroesophageal Reflux
8%
Ustekinumab
7%
Randomized Controlled Trial
7%
Proton Pump Inhibitor
7%
Gastrointestinal Hemorrhage
7%
Irritable Colon
7%
Clinical Study
6%
Immunomodulating Agent
5%
Budesonide
5%
Stenosis
5%
Indometacin
5%
Stomach Acid
5%
Monotherapy
5%
